One-Shot wonder? HPV vaccine trial could slash costs and save lives in africa
NCT ID NCT02834637
First seen Oct 31, 2025 · Last updated May 04, 2026 · Updated 26 times
Summary
This study tests whether a single dose of the HPV vaccine can protect Tanzanian girls aged 9-14 from cervical cancer just as well as the standard two or three doses. Around 900 girls will receive one, two, or three doses of either a bivalent or 9-valent HPV vaccine and be followed for up to 9 years. If one dose works, it could halve vaccination costs and make it easier to reach more girls in Africa.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mwanza Intervention Trials Unit (MITU)
Mwanza, Tanzania
Conditions
Explore the condition pages connected to this study.